Previous 10 | Next 10 |
Arbutus Biopharma Corporation (ABUS) Q3 2020 Earnings Conference Call November 5, 2020 08:45 ET Company Participants Pam Murphy - Investor Relations Bill Collier - President & Chief Executive Officer Dave Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike S...
bluebird bio (BLUE) -15% on Q3 earnings release.Hanesbrands (HBI) -14% on Q3 earnings release.Ping Identity Holding (PING) -13% on Q3 earnings release.Aptevo Therapeutics (APVO) -12% after providing updates on preliminary data in its ongoing APVO436 Phase 1 ...
Arbutus Biopharma (ABUS): Q3 GAAP EPS of -$0.27 misses by $0.05.Revenue of $1.52M (-50.3% Y/Y) misses by $0.18M.Press Release For further details see: Arbutus Biopharma EPS misses by $0.05, misses on revenue
Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the upcoming American Association for the Study of Liver Disease (AASLD) Conference ...
WARMINSTER, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includin...
WARMINSTER, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including...
Aligos Therapeutics has filed terms to raise $150 million in an IPO. The firm is developing treatments for chronic Hepatitis B and other liver and viral diseases. ALGS has produced intriguing early stage results and the IPO is reasonably priced, so is worth considering for long-te...
Should Biotech Penny Stocks Be On Your Watch List Right Now? What’s one of the top sectors to watch when it comes to penny stocks ? While some traders might say anything that’s moving, others pinpoint a few select sectors. In this case, biotech continues to offer m...
WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (includin...
Arbutus reports positive data for AB-729 for chronic hepatitis B. Marinus Pharmaceuticals hits primary endpoint in the Genetic Epilepsy trial. Novus Therapeutics on upswing on Anelixis acquisition. For further details see: Arbutus Reports Positive Hepatitis B Data, And O...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...